Home | Welcome to Contract Pharma   
Last Updated Monday, May 20 2013
Print RSS Feed

Breaking News

Related Searches: Financial Reports •
Financial Report: Hospira 1Q08

May 7, 2008
Hospira 1Q Revenues: $888.7 million (+14%) 1Q Earnings: $65.4 million (loss of $29.4 million 1Q07) Comments: In the Americas, pharmaceuticals revenues grew was 11% to $462.6 million. However, the "Other Pharmaceuticals" unit, which…  Read More »
Kendle

May 7, 2008
Patricia Williams has been appointed to the position of vice  president, commercial operations, Kendle. In this newly created  position, Ms. Williams will provide leadership for global contract  execution and negotiation with the…  Read More »
Financial Report: Kendle 1Q08

May 7, 2008
Kendle 1Q Revenues: $158.8 million (+20%) 1Q Earnings: $5.6 million (+33%) Comments: The company achieved record service revenues of $114.1   million and record new business awards of $180 million, both up 20%.   Total business a…  Read More »
Merck Cuts 1,200 U.S. Reps

May 6, 2008
Merck plans to reduce the size of its U.S. sales force by 15%, firing 1,200 reps. The move comes in the wake of slowing cholesterol drug sales as well as increased generic competition, according to the company.     "Merck is ta…  Read More »
Novartis Meningitis Vaccine Shows Response

May 6, 2008
New Phase III data for Novartis' Menveo show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to Sanofi Pasteur's Menactra. Infection with any of these f…  Read More »
Goodwin Biotechnology Completes Expansion

May 6, 2008
Goodwin Biotechnology, Inc. (GBI) has completed the expansion of its cGMP manufacturing space, doubling its capacity. The expansion includes the addition of a 200L and 500L stirred tank bioreactor train to its hollow fiber and perfusion capabilities,…  Read More »
BMS To Sell ConvaTec Unit

May 5, 2008
Bristol-Myers Squibb is selling its therapy and surgical care unit, ConvaTec, to two private equity firms, Nordic Capital and Avista Capital Partners for $4.1 billion. The sale, expected to close in the third quarter, is part of the company's strateg…  Read More »
Financial Report: AMRI 1Q08

May 5, 2008
AMRI 1Q Revenues: $53.6 million (+11%) 1Q Earnings: $4.7 million (+47%) Comments: Total contract revenue increased to $45.3 million in the quarter (+10%).  Discovery Services revenue was $13.3 million (+34%). Development and Small Scale…  Read More »
Eisai Corp.

May 5, 2008
Eisai Corp. of North America has appointed Cynthia Schwalm president of Eisai Inc. In her new role, Ms. Schwalm will have full operating responsibility for leading Eisai Inc., the U.S. commercial operation of Eisai Co., Ltd.     Ms.…  Read More »
QSV Wins cGMP Contract with Pfizer

May 2, 2008
QSV Biologics has been awarded a cGMP manufacturing contract for a recombinant protein under development by Pfizer. The protein, intended for clinical trials, will be manufactured at QSV's Edmonton facility in Canada. The project, to begin immediatel…  Read More »
Pfizer Invests in Clinical Bio-Facility

May 2, 2008
Pfizer plans to invest $297 million in a new biotech plant in Ireland for the production of experimental medicines. The facility will develop and produce small-scale quantities of products for Phase II and III trials, and will create approximately 10…  Read More »
Roche Extends Memory Pact

May 2, 2008
Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' lead nicotinic alpha-7 agonist drug candidate, MEM 3454, for neurological and psychiatric disorders. This decision triggers a $6 million milestone payment and…  Read More »
Merck's Vaccine Plant Gets Warning Letter

May 1, 2008
The FDA has issued a warning letter to Merck & Co. regarding several manufacturing deficiencies at its main vaccine plant in West Point, PA. The letter states that the FDA found "significant objectionable conditions" in the manufacture…  Read More »
GlaxoSmithKline

May 1, 2008
GlaxoSmithKline has made several changes to its corporate executive management team. The appointments will take effect on May 22 when Andrew Witty officially assumes the role of chief executive officer.     Mr. Witty remarked, "…  Read More »
Wyeth

May 1, 2008
Robert R. Ruffolo, Jr., Ph.D. will retire as president, Wyeth Research and senior vice president, Wyeth, later this year. He will be succeeded by Mikael Dohlsten, M.D., Ph.D.     Dr. Ruffolo joined Wyeth in November 2000 and has bee…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: